
Citius Oncology, Inc.
CTORNasdaqCIK 1851484HealthcareFiscal year ends Sep 30
Reports and events: 93 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2025-01-0608:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-000953 |
| 2024-12-2717:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-24-113159 |
| 2024-12-2717:00 ET | 10-K | Annual reportPeriod 2024-09-30 | 0001213900-24-113150 |
| 2024-11-1208:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-096269 |
| 2024-09-1308:30 ET | 8-K | 1.01 Entry into a material agreement | 0001213900-24-078287 |
| 2024-09-0516:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-076111 |
| 2024-08-2616:15 ET | 8-K/A | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001213900-24-072598 |
| 2024-08-1617:25 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 4.01 Change of auditor; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.06 Item not in the standard list; 9.01 Financial statements and exhibits | 0001213900-24-070335 |
| 2024-08-1616:34 ET | SC 13D | Ownership report, active investor | 0001213900-24-070284 |
| 2024-08-1512:53 ET | SC 13D/A | Ownership report, active investor, amended | 0001493152-24-032563 |
| 2024-08-0916:22 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001493152-24-030991 |
| 2024-08-0520:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-030145 |
| 2024-07-1915:39 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-24-028500 |
| 2024-06-1813:35 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-24-024236 |
| 2024-06-0617:28 ET | 8-K | 8.01 Other events | 0001493152-24-022977 |
| 2024-05-2115:07 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-24-020866 |
| 2024-05-2017:27 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001493152-24-020783 |
| 2024-04-2916:45 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-24-017024 |
| 2024-04-1617:00 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001493152-24-014850 |
| 2024-01-1816:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-002896 |
| 2024-01-1016:42 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-001958 |
| 2024-01-0816:46 ET | DEF 14A | Proxy statementPeriod 2024-01-08 | 0001493152-24-001720 |
| 2023-11-2017:25 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001493152-23-042170 |
| 2023-10-2407:41 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-23-038045 |
| 2023-10-1817:20 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-23-037635 |
| 2023-08-1614:44 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001493152-23-029131 |
| 2023-07-1816:15 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-23-024835 |
| 2023-05-1516:19 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001493152-23-017394 |
| 2023-04-1716:18 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001493152-23-012545 |
| 2022-12-0617:23 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-22-034614 |
| 2022-11-2816:55 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001493152-22-033847 |
| 2022-10-2816:59 ET | SC 13D | Ownership report, active investor | 0001493152-22-029872 |
| 2022-10-2417:26 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-22-029450 |
| 2022-10-1916:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-22-028873 |
| 2022-09-1217:22 ET | S-1/A | Registration statement, amended | 0001493152-22-025658 |
| 2022-07-2915:25 ET | S-1/A | Registration statement, amended | 0001493152-22-020683 |
| 2022-05-2421:52 ET | S-1/A | Registration statement, amended | 0001493152-22-014854 |
| 2022-05-1117:21 ET | S-1/A | Registration statement, amended | 0001493152-22-012880 |
| 2022-04-0116:29 ET | S-1/A | Registration statement, amended | 0001493152-22-008828 |
| 2022-03-0817:10 ET | S-1/A | Registration statement, amended | 0001493152-22-006313 |
| 2021-08-2017:28 ET | S-1/A | Registration statement, amended | 0001493152-21-020860 |
| 2021-06-3017:45 ET | S-1/A | Registration statement, amended | 0001493152-21-015601 |
| 2021-05-1918:37 ET | S-1 | Registration statement | 0001493152-21-012185 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 14, 2026, 21:33 ET. Listed shows no prices and gives no investment advice.